Giants of Cancer Care® Program Inductees
Lung Cancer
David P. Carbone, MD, PhD
The Ohio State University Comprehensive Cancer Center
- Carbone is director of the James Thoracic Center, coleader of the Translational Therapeutics Program, director of the Thoracic Oncology Center, and the Barbara J. Bonner Chair in Lung Cancer Research at The Ohio State University Comprehensive Cancer Center–James.
- His research focus is the molecular genetics of lung tumors, which includes understanding the specific cells and genetic markers in each patient’s lung cancer and developing targeted agents to these molecularly driven malignancies.
- Carbone is highly regarded for developing molecular profiling in lung cancers and preneoplasia, especially mass spectrometry– based proteomics, and the development of novel therapeutics in response to those molecular factors. For example, he was senior author on a multicohort, cross-institutional study showing that a matrix-assisted laser desorption ionization mass spectrometry algorithm was able to classify patients with non–small cell lung cancer as having good or positive outcomes following EGFR tyrosine kinase inhibitor therapy.
- He has been an investigator on multiple phase 3 trials, including CheckMate 9LA (NCT03215706) of nivolumab (Opdivo) plus ipilimumab (Yervoy) plus chemotherapy in non–small cell lung cancer.
- Carbone is also known for his research and advocacy efforts that nonsmokers, not only smokers, can be susceptible to lung cancer.
- His previous positions include director of the Thoracic/Head and Neck Cancer Program at Vanderbilt-Ingram Cancer Center, where he also served as director and principal investigator of the Vanderbilt Specialized Program of Research Excellence in Lung Cancer and principal investigator of the Strategic Partnering to Evaluate Cancer Signatures in Lung Cancer UO1 consortium. He is also a past president of the International Association for the Study of Lung Cancer (2016-2017).
Home
SUPPORTED BY
